In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

The soaring demand for antidiabetic and weight-loss drugs has lured in many biotech and big Pharma companies. Onto this ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Find Insulin Molecule stock video, 4K footage, and other HD footage from iStock. Get higher quality Insulin Molecule content, for less—All of our 4K video clips are the same price as HD. Video Back ...

As a result, semaglutide and its fellow glucagon-like peptide-1 drugs are ... word for whatever chemical messenger or signaling molecule attaches to the receptor, activating it.

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral tablet, ASC30, in obese individuals. The study, which involved 40 obese ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

epinephrine and glucagon rapidly increase the amount of active phosphorylase in pre-incubated liver slices 1,2. In order to study the nature of the change in the phosphorylase molecule ...

StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Free Report) in a research report report published on Wednesday. The brokerage issued a sell rating on the biotechnology ...

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the ...